iBio, Inc.

iBio announced new preclinical data for its IBIO-610 Activin E antibody candidate from an obese non-human primate study. A single dose of IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks. The data also showed IBIO-610's potential for fat-selective weight loss while preserving lean mass, and when combined with semaglutide, it reduced lean mass loss by 73% compared to semaglutide alone. These findings support its potential as a stand-alone or complementary therapy for obesity.

iBio, Inc. announced new preclinical data for its Activin E antibody candidate, IBIO-610, in obese non-human primates. A single dose of IBIO-610 achieved up to 98% inhibition of active Activin E, sustained for eight weeks. When combined with semaglutide, IBIO-610 demonstrated greater visceral and total fat loss while reducing lean mass loss by 73% compared to semaglutide alone. These findings support IBIO-610's potential as a differentiated, long-acting therapy for obesity, with the full data to be presented at the 2026 EASD Annual Meeting.

iBio, Inc. announced that its Chief Executive Officer and Chief Financial Officer will participate in two upcoming investor conferences. Dr. Martin Brenner and Mr. Felipe Duran will attend the Jefferies Global Healthcare Conference on June 4, 2026, in New York, and the Leerink Partners Therapeutics Forum: I&I and Metabolism Conference on July 14-15, 2026, in Boston. The executives will present and hold one-on-one investor meetings at these events.

iBio, Inc. announced the dosing of the first participant in its Phase 1 clinical trial for IBIO-600, marking its transition to a clinical-stage biotechnology company. IBIO-600 is a long-acting monoclonal antibody designed to target myostatin and GDF11, aiming to preserve muscle and improve body composition during weight reduction, potentially in combination with GLP-1-based therapies. The study will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in approximately 32 adults with overweight and obesity, with results expected in the second half of 2027.

iBio reported a net loss of $(7.73) million for the three months ended March 31, 2026, and $(22.44) million for the nine months ended March 31, 2026. Despite increased operating expenses, the company significantly improved its liquidity position, ending the period with $47.63 million in cash and cash equivalents and $27.17 million in investments in debt securities, totaling $74.8 million. This enhanced financial standing, bolstered by recent equity raises and warrant exercises, is expected to fund operations for at least the next 12 months, addressing prior going concern doubts. The company also anticipates IBIO-600 to enter Phase 1a clinical trials in Q2 2026 and IBIO-610 in H1 2027.

iBio, Inc. reported its Q3 fiscal year 2026 financial results, alongside significant corporate advancements. The company received regulatory clearance to initiate its Phase 1 clinical trial for IBIO-600 in Australia, a key step for its obesity therapy. iBio also expanded its pipeline into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) and presented new preclinical data for IBIO-610, showing visceral fat reduction in obese non-human primates. Financially, iBio reported no revenue, an increased net loss of $7.7 million, and ended the quarter with $74.8 million in cash, cash equivalents, and investments.

iBio, Inc. announced the appointment of Dr. Elizabeth Stoner, M.D., M.S., to its Board of Directors and Compensation Committee, effective May 7, 2026. Dr. Stoner brings over 35 years of research and development leadership, including roles at MPM BioImpact, Semma Therapeutics, Rhythm Pharmaceuticals, and Merck Research Laboratories. Concurrently, Evert Schimmelpennink resigned from the Board and Compensation Committee, with his departure not attributed to any disagreement with the company.

iBio, Inc. announced the appointment of Elizabeth Stoner, M.D., M.S. to its Board of Directors as an independent member and to the Compensation Committee. Dr. Stoner replaces Eef Schimmelpennink, who stepped down from the Board. Dr. Stoner brings over 35 years of research and development leadership experience, including roles at MPM BioImpact, Semma Therapeutics, Rhythm Pharmaceuticals, and Merck Research Laboratories, which will be valuable as iBio advances its clinical programs.

iBio, Inc. announced it received Clinical Trial Notification acknowledgement and ethics approval to initiate a first-in-human Phase 1 clinical trial for IBIO-600 in Australia. The company expects to dose the first participants in the second quarter of 2026. Additionally, iBio filed an amendment to correct a typographical error, confirming Series G warrants will expire on May 20, 2026, and updated outstanding warrant and common stock figures.

iBio, Inc. has announced the initiation of a first-in-human clinical trial for its drug candidate, IBIO-600, in Australia. The company received Clinical Trial Notification acknowledgement from Australia’s Therapeutic Goods Administration and ethics approval from a Human Research Ethics Committee, paving the way for the trial. This marks a significant step forward in the development of IBIO-600, expanding iBio's clinical pipeline. The first participants in the trial are expected to be dosed during the second quarter of 2026.